sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed a disclosure under Form 8.3 with the Irish Takeover Panel concerning its interests in Avadel Pharmaceuticals plc. The disclosure was made for securities worth over 1% of Avadel, according to the Irish Takeover Panel Act, 1997, and Takeover Rules, 2022.
As of November 12, 2025, Vanguard owns 5,524,254 ordinary shares, representing 5.67% of Avadel's relevant securities. Additionally, Vanguard purchased 711 ordinary shares at a price of 19.15 USD per unit. There were no cash-settled or stock-settled derivatives reported.
Vanguard reported no indemnity or other deal arrangements, nor any agreements relating to options or derivative voting rights. No Supplemental Form 8 was attached, indicating straightforward, non-complex holdings.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.